Gilead narrows criteria for HCV drugs access program

Gilead Sciences Inc. (NASDAQ:GILD) has narrowed the eligibility criteria for Support Path, its patient access program for HCV treatments Sovaldi sofosbuvir and Harvoni ledipasvir/sofosbuvir. The program offers co-pay coupons or free treatment for eligible patients who lack insurance or require financial assistance.

Since July 1, Support Path no longer offers the drugs to HCV patients whose insurance providers limit access to Sovaldi and Harvoni based on factors such as fibrosis score or treatment duration, or who prefer or exclusively cover another therapy such as Viekira Pak from AbbVie Inc. (NYSE:ABBV) in their formularies. ...